MANE — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-11

• ncompletion of our underwritten public offering, or the Follow-On Public Offering, pursuant to which we issued and sold an aggregate of 4,420,358 shares of common stock at a public offering price of $100.00 per share, including 576,568 shares pursuant to the full exercise of the underwriters’ option…

• nConcurrently with the Follow On Public Offering, on May 1, 2026, we closed a private placement, or the Private Placement, pursuant to a Securities Purchase Agreement, or the Purchase Agreement, dated April 29, 2026, among us and certain entities affiliated with Montanova Capital (formerly known as …

• Subsequent to the second quarter of 2026, the following milestones have been achieved:

• ncompletion of enrollment in our registration-directed Phase 2/3 trial, Study ‘306’, of VDPHL01 in female patients with mild-to-moderate PHL. We expect to report topline data from this study in the first half of 2027.

• On July 15, 2026, we announced positive topline results from Study ‘207’ evaluating VDPHL01 in females with mild-to-moderate pattern hair loss. Study '207' is a multicenter Phase 2 open label study in adult 21 male and 28 adult female pattern hair loss patients to obtain proof of concept for the saf…

Text removed vs the prior filing · source: 10-Q · 2026-05-12

• Subsequent to the first quarter of 2026, the following milestones have been achieved:

• nIn May 2026, we completed our underwritten public offering, or the Follow-On Public Offering, of 4,420,358 shares of our common stock, par value $0.00001 per share, or Common Stock, at a public offering price of $100.00 per share, including 576,568 shares pursuant to the full exercise of the underw…

• before deducting underwriting fees and discounts. Concurrently with the Follow On Public Offering, on May 1, 2026, we closed a private placement, or the Private Placement, pursuant to a Securities Purchase Agreement, or the Purchase Agreement, dated April 29, 2026, among us and certain entities affi…

• Additionally, the Company expects to release 12-month data from this 302 study and additional Phase 2 data in 2026.

• Comparison of the three months ended March 31, 2026 and 2025

Text removed vs the prior filing · source: 10-Q · 2026-05-12

• A significant portion of our total outstanding shares are, as of the date of filing this Quarterly Report on Form 10-Q, restricted from immediate resale but may be sold into the market upon expiration of the lock-up agreement entered into in connection with our IPO, which could cause the market pric…

• Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales upon the expiration of the lock-up agreements entered into by holders of substantially all of our common stock outstanding immediately prior to our IPO, or the perception in the mark…

• Additionally, holders of an aggregate of approximately 23,594,826 shares of our common stock, excluding shares purchased by non-affiliates in or after the IPO, will have rights, subject to conditions, to require us to file registration statements covering their shares or to include their shares in r…

Text added vs the prior filing · source: 10-Q · 2026-08-11

• During our fiscal quarter ended June 30, 2026, no director or “officer” (as defined in Rule 16a-1(f) under the Exchange Act) of the Company entered into, modified or terminated contracts, instructions or written plans for the purchase or sale of our common stock that are intended to satisfy the affi…

Text removed vs the prior filing · source: 10-Q · 2026-05-12

• During our fiscal quarter ended March 31, 2026, certain of our directors or “officers,” (as defined in Rule 16a-1(f) under the Exchange Act) entered into a contract, instruction or written plan for the purchase or sale of our securities that is intended to satisfy the conditions specified in Rule 10…

• We describe the material terms of these Rule 10b5-1 trading plans in the table below.

• Director/OfficerAction and Date of ActionCommencement of Trading Period

• Maximum Number of Securities to be Purchased or Sold Pursuant to the Rule 10b5-1 Trading Plan (2)

• (1)The plan is subject to earlier termination under certain circumstances specified in the plan, including upon the sale or purchase (as applicable) of all shares subject to the plan and upon either party to a plan giving notice of termination within the time prescribed under the plan.